Breaking News

Saturday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Week in review: How Trump's policies moved stocks » 09:06
08/01/20
08/01
09:06
08/01/20
09:06
MSFT

Microsoft

$205.00 /

+1.135 (+0.56%)

, PFE

Pfizer

$38.48 /

-0.27 (-0.70%)

, AZN

AstraZeneca

$55.77 /

-2.13 (-3.68%)

, BMY

Bristol-Myers

$58.66 /

-0.22 (-0.37%)

, LLY

Eli Lilly

$150.24 /

-2.71 (-1.77%)

, GSK

GlaxoSmithKline

$40.31 /

+0.045 (+0.11%)

, JNJ

Johnson & Johnson

$145.78 /

-1.09 (-0.74%)

, MRK

Merck

$80.26 /

+1.21 (+1.53%)

, NVS

Novartis

$82.09 /

-2.115 (-2.51%)

, SNY

Sanofi

$52.43 /

-0.1 (-0.19%)

, MRNA

Moderna

$74.10 /

-3.5 (-4.51%)

, SNAP

Snap

$22.41 /

+ (+0.00%)

, TWTR

Twitter

$36.39 /

-0.34 (-0.93%)

, FB

Facebook

$253.82 /

+19.19 (+8.18%)

, GOOG

Alphabet

$1,482.46 /

-52.125 (-3.40%)

, GOOGL

Alphabet Class A

$1,487.69 /

-48.81 (-3.18%)

, AMZN

Amazon.com

$3,165.00 /

+114.03 (+3.74%)

, AAPL

Apple

$425.02 /

+39.88 (+10.35%)

, KODK

Eastman Kodak

$22.30 /

-7.53 (-25.24%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

Catch up on the top…

Open Full Text

ShowHide Related Items >><<
TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

KODK Eastman Kodak
$22.30 /

-7.53 (-25.24%)

JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOGL Alphabet Class A
$1,487.69 /

-48.81 (-3.18%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

FB Facebook
$253.82 /

+19.19 (+8.18%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

07/31/20 Stifel
Citrix disclosure points to $1B commitment, most likely to Azure, says Stifel
07/27/20 Morgan Stanley
Morgan Stanley downgrades Software industry view to In-Line from Attractive
07/23/20
Fly Intel: Top five analyst downgrades
07/23/20 Wedbush
Microsoft remains top cloud name at Wedbush
PFE Pfizer
$38.48 /

-0.27 (-0.70%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
07/22/20 Morgan Stanley
Morgan Stanley sees 'encouraging news' coming in near-term for Bristol-Myers
LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

07/31/20 Barclays
Barclays backs Underweight on GSK after 'challenging' Q2
07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

07/29/20 Laidlaw
Curis initiated with a Buy at Laidlaw
07/17/20 Goldman Sachs
J&J valuation discount to S&P 500 'too wide,' says Goldman Sachs
07/17/20 Citi
Johnson & Johnson price target raised to $170 from $165 at Citi
MRK Merck
$80.26 /

+1.21 (+1.53%)

07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
NVS Novartis
$82.09 /

-2.115 (-2.51%)

07/28/20 Morgan Stanley
Novartis price target raised to CHF 93 from CHF 91 at Morgan Stanley
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
SNY Sanofi
$52.43 /

-0.1 (-0.19%)

07/31/20 JPMorgan
Sanofi price target raised to EUR 106 from EUR 103 at JPMorgan
07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
MRNA Moderna
$74.10 /

-3.5 (-4.51%)

07/27/20 Piper Sandler
Piper reiterates $134 Moderna target on start of Phase III vaccine trial
07/27/20 BMO Capital
Moderna price target lowered to $94 from $112 at BMO Capital
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
SNAP Snap
$22.41 /

+ (+0.00%)

07/28/20 Morgan Stanley
Morgan Stanley lowers near-term, long-term forecasts for Roku
07/22/20
Fly Intel: Top five analyst downgrades
07/22/20 Oppenheimer
Snap price target raised to $28 from $18 at Oppenheimer
07/22/20 JPMorgan
Snap should be bought on any meaningful pullback, says JPMorgan
TWTR Twitter
$36.39 /

-0.34 (-0.93%)

07/24/20 SunTrust
Twitter price target raised to $40 from $32 at SunTrust
07/24/20 Argus
Twitter price target raised to $46 from $40 at Argus
07/24/20 Canaccord
Twitter price target raised to $40 from $32 at Canaccord
FB Facebook
$253.82 /

+19.19 (+8.18%)

07/31/20
Facebook price target raised to $300 from $290 at JPMorgan
07/31/20 Wedbush
Facebook price target raised to $300 from $250 at Wedbush
07/31/20 RBC Capital
Facebook price target raised to $320 from $271 at RBC Capital
07/31/20 Raymond James
Facebook price target raised to $280 from $240 at Raymond James
GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

07/31/20
Fly Intel: Top five analyst downgrades
07/31/20 Guggenheim
Alphabet price target raised to $1,725 from $1,580 at Guggenheim
07/31/20 Raymond James
Alphabet price target raised to $1,700 from $1,425 at Raymond James
07/31/20 Oppenheimer
Alphabet price target raised to $1,685 from $1,445 at Oppenheimer
GOOGL Alphabet Class A
$1,487.69 /

-48.81 (-3.18%)

07/31/20 RBC Capital
Alphabet price target raised to $1,700 from $1,500 at RBC Capital
07/31/20 Morgan Stanley
Alphabet price target raised to $1,760 from $1,700 at Morgan Stanley
07/31/20 Barclays
Alphabet price target raised to $1,800 from $1,600 at Barclays
AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

07/31/20 BMO Capital
Amazon.com price target raised to $3,700 from $3,500 at BMO Capital
07/31/20 RBC Capital
Amazon.com price target raised to $3,800 from $3,300 at RBC Capital
07/31/20 Guggenheim
Amazon.com price target raised to $3,600 from $2,700 at Guggenheim
07/31/20 Goldman Sachs
Amazon.com price target raised to $4,200 from $3,800 at Goldman Sachs
AAPL Apple
$425.02 /

+39.88 (+10.35%)

07/31/20 Canaccord
Canaccord boosts Apple target to $460 after 'impressive' quarter
07/31/20 RBC Capital
Apple price target raised to $445 from $390 at RBC Capital
07/31/20
Apple price target raised to $460 from $425 at JPMorgan
07/31/20 Loop Capital
Apple price target raised to $376 from $330 at Loop Capital
KODK Eastman Kodak
$22.30 /

-7.53 (-25.24%)

RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

FB Facebook
$253.82 /

+19.19 (+8.18%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

  • 19
    May
  • 12
    Feb
TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

KODK Eastman Kodak
$22.30 /

-7.53 (-25.24%)

JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOGL Alphabet Class A
$1,487.69 /

-48.81 (-3.18%)

FB Facebook
$253.82 /

+19.19 (+8.18%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

KODK Eastman Kodak
$22.30 /

-7.53 (-25.24%)

JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOGL Alphabet Class A
$1,487.69 /

-48.81 (-3.18%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

FB Facebook
$253.82 /

+19.19 (+8.18%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

Friday
Recommendations
GlycoMimetics price target lowered to $15 from $16 at H.C. Wainwright » 12:38
07/31/20
07/31
12:38
07/31/20
12:38
GLYC

GlycoMimetics

$3.88 /

-0.27 (-6.51%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Edward White lowered the firm's price target on GlycoMimetics to $15 from $16 and keeps a Buy rating on the shares after the company reported Q2 results. The analyst said management believes it has a cash runway into mid- to 2H22, which he believes will get the company through the Phase 3 topline data readout for uproleselan. Whited added he lowered his price target because of a higher share count due to the recent capital raise through the use of the company's ATM.

ShowHide Related Items >><<
GLYC GlycoMimetics
$3.88 /

-0.27 (-6.51%)

GLYC GlycoMimetics
$3.88 /

-0.27 (-6.51%)

07/22/20 Roth Capital
Roth reiterates Buy on GlycoMimetics after management meeting
06/12/20 Roth Capital
GlycoMimetics analysis of rivipansel study hints at path to approval, Roth says
02/11/20 Roth Capital
GlycoMimetics termination notice from Pfizer no surprise, says Roth Capital
12/10/19 Roth Capital
GlycoMimetics' uproleselan presentation 'very exciting,' says Roth Capital
GLYC GlycoMimetics
$3.88 /

-0.27 (-6.51%)

Earnings
GlycoMimetics reports Q2 EPS (32c), consensus (38c) » 08:10
07/31/20
07/31
08:10
07/31/20
08:10
GLYC

GlycoMimetics

$4.15 /

-0.14 (-3.26%)

"The second quarter…

"The second quarter was quite productive as we noted strong enrollment in our company-sponsored pivotal trial of uproleselan in relapsed/refractory AML. Though we did see a slow down early in the COVID crisis, we were pleased to see enrollment pick back up later in the quarter. This was an important achievement in the face of the COVID-19 pandemic, and we are able to maintain prior guidance that we expect to complete enrollment in the second half of 2021. Also important were new data from a post hoc analysis of the rivipansel Phase 3 study that showed that patients treated with rivipansel within approximately 26 hours of the onset of pain in their crisis experienced statistically significant improvements in the primary efficacy endpoint of time to readiness for discharge compared to placebo. These data provide a foundation, we believe, for us to discuss with the FDA whether there may be a path forward for rivipansel in acute VOC," commented Rachel King, CEO.

ShowHide Related Items >><<
GLYC GlycoMimetics
$4.15 /

-0.14 (-3.26%)

GLYC GlycoMimetics
$4.15 /

-0.14 (-3.26%)

07/22/20 Roth Capital
Roth reiterates Buy on GlycoMimetics after management meeting
06/12/20 Roth Capital
GlycoMimetics analysis of rivipansel study hints at path to approval, Roth says
02/11/20 Roth Capital
GlycoMimetics termination notice from Pfizer no surprise, says Roth Capital
12/10/19 Roth Capital
GlycoMimetics' uproleselan presentation 'very exciting,' says Roth Capital
GLYC GlycoMimetics
$4.15 /

-0.14 (-3.26%)

Earnings
Pfizer, BioNTech to supply Japan with 120M doses of BNT162 vaccine candidate » 05:53
07/31/20
07/31
05:53
07/31/20
05:53
PFE

Pfizer

$38.75 /

+0.24 (+0.62%)

, BNTX

BioNTech

$84.02 /

+1.6 (+1.94%)

Pfizer (PFE) and BioNTech…

Pfizer (PFE) and BioNTech SE (BNTX) said in a release, "Pfizer and BioNTech announced an agreement with the Ministry of Health, Labour and Welfare, or MHLW, in Japan to supply 120 million doses of BNT162 mRNA-based vaccine candidate against SARS-CoV2, subject to clinical success and regulatory approval, beginning in 2021. Financial details of the agreement were not disclosed, but the terms were based on the timing of delivery and the volume of doses. As requested by the Government of Japan, deliveries of the vaccine candidate are planned for the first half of 2021."

ShowHide Related Items >><<
PFE Pfizer
$38.75 /

+0.24 (+0.62%)

BNTX BioNTech
$84.02 /

+1.6 (+1.94%)

PFE Pfizer
$38.75 /

+0.24 (+0.62%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
BNTX BioNTech
$84.02 /

+1.6 (+1.94%)

07/21/20
Fly Intel: Top five analyst upgrades
07/21/20 Canaccord
BioNTech price target raised to $97 from $75 at Canaccord
PFE Pfizer
$38.75 /

+0.24 (+0.62%)

BNTX BioNTech
$84.02 /

+1.6 (+1.94%)

  • 23
    Jul
  • 06
    Feb
  • 10
    Oct
PFE Pfizer
$38.75 /

+0.24 (+0.62%)

BNTX BioNTech
$84.02 /

+1.6 (+1.94%)

PFE Pfizer
$38.75 /

+0.24 (+0.62%)

BNTX BioNTech
$84.02 /

+1.6 (+1.94%)

PFE Pfizer
$38.75 /

+0.24 (+0.62%)

BNTX BioNTech
$84.02 /

+1.6 (+1.94%)

Thursday
Recommendations
BofA says hard to compare Moderna COVID data to competing preclinical data » 11:15
07/30/20
07/30
11:15
07/30/20
11:15
MRNA

Moderna

$77.48 /

-2 (-2.52%)

, PFE

Pfizer

$38.32 /

-0.19 (-0.49%)

, BNTX

BioNTech

$83.99 /

+1.575 (+1.91%)

, AZN

AstraZeneca

$57.30 /

+0.73 (+1.29%)

, MRK

Merck

$78.31 /

-1.02 (-1.29%)

, JNJ

Johnson & Johnson

$146.58 /

+0.04 (+0.03%)

Following the recent…

Following the recent publication of preclinical non-human primate data for Moderna's (MRNA) COVID-19 vaccine, mRNA-1273, BofA analyst Geoff Meacham said the data appear supportive of the "more important human data already published" from the phase 1 trial. While some may suggest transmissibility after vaccination with Moderna's vaccine will be lower than with the COVID-19 vaccine from Oxford and AstraZeneca (AZN), now known as AZD1222, "confounders in the data clouds any conclusion," he said. Meachem keeps a Neutral rating and $85 price target on Moderna, citing competing vaccines from Pfizer (PFE), AstraZeneca, J&J (JNJ), Merck (MRK) and others as well as his view of the "questionable economics to Moderna if a vaccine is approved."

ShowHide Related Items >><<
PFE Pfizer
$38.32 /

-0.19 (-0.49%)

MRNA Moderna
$77.48 /

-2 (-2.52%)

MRK Merck
$78.31 /

-1.02 (-1.29%)

JNJ Johnson & Johnson
$146.58 /

+0.04 (+0.03%)

BNTX BioNTech
$83.99 /

+1.575 (+1.91%)

AZN AstraZeneca
$57.30 /

+0.73 (+1.29%)

MRNA Moderna
$77.48 /

-2 (-2.52%)

07/27/20 Piper Sandler
Piper reiterates $134 Moderna target on start of Phase III vaccine trial
07/27/20 BMO Capital
Moderna price target lowered to $94 from $112 at BMO Capital
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/23/20 SVB Leerink
Moderna initiated with a Market Perform at SVB Leerink
PFE Pfizer
$38.32 /

-0.19 (-0.49%)

07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
BNTX BioNTech
$83.99 /

+1.575 (+1.91%)

07/21/20
Fly Intel: Top five analyst upgrades
07/21/20 Canaccord
BioNTech price target raised to $97 from $75 at Canaccord
07/20/20 BofA
BioNTech upgraded to Buy from Neutral at BofA
AZN AstraZeneca
$57.30 /

+0.73 (+1.29%)

07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
MRK Merck
$78.31 /

-1.02 (-1.29%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
JNJ Johnson & Johnson
$146.58 /

+0.04 (+0.03%)

07/29/20 Laidlaw
Curis initiated with a Buy at Laidlaw
07/17/20 Goldman Sachs
J&J valuation discount to S&P 500 'too wide,' says Goldman Sachs
07/17/20 Citi
Johnson & Johnson price target raised to $170 from $165 at Citi
07/16/20 Goldman Sachs
J&J delay to robotic surgery program a positive for Intuitive, says Goldman
PFE Pfizer
$38.32 /

-0.19 (-0.49%)

MRNA Moderna
$77.48 /

-2 (-2.52%)

MRK Merck
$78.31 /

-1.02 (-1.29%)

JNJ Johnson & Johnson
$146.58 /

+0.04 (+0.03%)

BNTX BioNTech
$83.99 /

+1.575 (+1.91%)

AZN AstraZeneca
$57.30 /

+0.73 (+1.29%)

  • 23
    Jul
  • 19
    May
  • 12
    Feb
  • 06
    Feb
  • 10
    Oct
PFE Pfizer
$38.32 /

-0.19 (-0.49%)

MRNA Moderna
$77.48 /

-2 (-2.52%)

MRK Merck
$78.31 /

-1.02 (-1.29%)

JNJ Johnson & Johnson
$146.58 /

+0.04 (+0.03%)

BNTX BioNTech
$83.99 /

+1.575 (+1.91%)

PFE Pfizer
$38.32 /

-0.19 (-0.49%)

MRNA Moderna
$77.48 /

-2 (-2.52%)

MRK Merck
$78.31 /

-1.02 (-1.29%)

JNJ Johnson & Johnson
$146.58 /

+0.04 (+0.03%)

BNTX BioNTech
$83.99 /

+1.575 (+1.91%)

AZN AstraZeneca
$57.30 /

+0.73 (+1.29%)

PFE Pfizer
$38.32 /

-0.19 (-0.49%)

MRNA Moderna
$77.48 /

-2 (-2.52%)

MRK Merck
$78.31 /

-1.02 (-1.29%)

JNJ Johnson & Johnson
$146.58 /

+0.04 (+0.03%)

BNTX BioNTech
$83.99 /

+1.575 (+1.91%)

AZN AstraZeneca
$57.30 /

+0.73 (+1.29%)

Hot Stocks
Drug prices will soon be 'lowered massively' in U.S., Trump tweets » 09:51
07/30/20
07/30
09:51
07/30/20
09:51
JNJ

Johnson & Johnson

$147.11 /

+0.57 (+0.39%)

, LLY

Eli Lilly

$156.79 /

-5.03 (-3.11%)

, MRK

Merck

$78.20 /

-1.13 (-1.42%)

, PFE

Pfizer

$38.45 /

-0.06 (-0.16%)

, SNY

Sanofi

$51.85 /

-0.98 (-1.86%)

, AZN

AstraZeneca

$56.96 /

+0.39 (+0.69%)

, GSK

GlaxoSmithKline

$39.78 /

-0.82 (-2.02%)

, NVS

Novartis

$83.27 /

-1.08 (-1.28%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$58.58 /

-0.58 (-0.98%)

President Donald Trump…

President Donald Trump tweeted: "Drug prices will soon be lowered massively. Big Pharma (Drug Companies) are advertising against me like crazy because lower prices mean less profit. When you watch a Fake Ad, just think lower drug prices!!!" Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

ShowHide Related Items >><<
SNY Sanofi
$51.85 /

-0.98 (-1.86%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.45 /

-0.06 (-0.16%)

NVS Novartis
$83.27 /

-1.08 (-1.28%)

MRK Merck
$78.20 /

-1.13 (-1.42%)

LLY Eli Lilly
$156.79 /

-5.03 (-3.11%)

JNJ Johnson & Johnson
$147.11 /

+0.57 (+0.39%)

GSK GlaxoSmithKline
$39.78 /

-0.82 (-2.02%)

BMY Bristol-Myers
$58.58 /

-0.58 (-0.98%)

AZN AstraZeneca
$56.96 /

+0.39 (+0.69%)

JNJ Johnson & Johnson
$147.11 /

+0.57 (+0.39%)

07/29/20 Laidlaw
Curis initiated with a Buy at Laidlaw
07/17/20 Goldman Sachs
J&J valuation discount to S&P 500 'too wide,' says Goldman Sachs
07/17/20 Citi
Johnson & Johnson price target raised to $170 from $165 at Citi
07/16/20 Goldman Sachs
J&J delay to robotic surgery program a positive for Intuitive, says Goldman
LLY Eli Lilly
$156.79 /

-5.03 (-3.11%)

07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
07/09/20 Morgan Stanley
Eli Lilly won't publish Phase 1 COVID antibody data, says Morgan Stanley
MRK Merck
$78.20 /

-1.13 (-1.42%)

07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
PFE Pfizer
$38.45 /

-0.06 (-0.16%)

07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
SNY Sanofi
$51.85 /

-0.98 (-1.86%)

07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
AZN AstraZeneca
$56.96 /

+0.39 (+0.69%)

07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
GSK GlaxoSmithKline
$39.78 /

-0.82 (-2.02%)

07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
NVS Novartis
$83.27 /

-1.08 (-1.28%)

07/28/20 Morgan Stanley
Novartis price target raised to CHF 93 from CHF 91 at Morgan Stanley
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
BMY Bristol-Myers
$58.58 /

-0.58 (-0.98%)

07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
07/22/20 Morgan Stanley
Morgan Stanley sees 'encouraging news' coming in near-term for Bristol-Myers
SNY Sanofi
$51.85 /

-0.98 (-1.86%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.45 /

-0.06 (-0.16%)

NVS Novartis
$83.27 /

-1.08 (-1.28%)

MRK Merck
$78.20 /

-1.13 (-1.42%)

LLY Eli Lilly
$156.79 /

-5.03 (-3.11%)

JNJ Johnson & Johnson
$147.11 /

+0.57 (+0.39%)

GSK GlaxoSmithKline
$39.78 /

-0.82 (-2.02%)

BMY Bristol-Myers
$58.58 /

-0.58 (-0.98%)

AZN AstraZeneca
$56.96 /

+0.39 (+0.69%)

SNY Sanofi
$51.85 /

-0.98 (-1.86%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.45 /

-0.06 (-0.16%)

NVS Novartis
$83.27 /

-1.08 (-1.28%)

MRK Merck
$78.20 /

-1.13 (-1.42%)

LLY Eli Lilly
$156.79 /

-5.03 (-3.11%)

JNJ Johnson & Johnson
$147.11 /

+0.57 (+0.39%)

GSK GlaxoSmithKline
$39.78 /

-0.82 (-2.02%)

BMY Bristol-Myers
$58.58 /

-0.58 (-0.98%)

SNY Sanofi
$51.85 /

-0.98 (-1.86%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.45 /

-0.06 (-0.16%)

NVS Novartis
$83.27 /

-1.08 (-1.28%)

MRK Merck
$78.20 /

-1.13 (-1.42%)

LLY Eli Lilly
$156.79 /

-5.03 (-3.11%)

JNJ Johnson & Johnson
$147.11 /

+0.57 (+0.39%)

GSK GlaxoSmithKline
$39.78 /

-0.82 (-2.02%)

BMY Bristol-Myers
$58.58 /

-0.58 (-0.98%)

AZN AstraZeneca
$56.96 /

+0.39 (+0.69%)

SNY Sanofi
$51.85 /

-0.98 (-1.86%)

PFE Pfizer
$38.45 /

-0.06 (-0.16%)

NVS Novartis
$83.27 /

-1.08 (-1.28%)

MRK Merck
$78.20 /

-1.13 (-1.42%)

LLY Eli Lilly
$156.79 /

-5.03 (-3.11%)

JNJ Johnson & Johnson
$147.11 /

+0.57 (+0.39%)

GSK GlaxoSmithKline
$39.78 /

-0.82 (-2.02%)

BMY Bristol-Myers
$58.58 /

-0.58 (-0.98%)

AZN AstraZeneca
$56.96 /

+0.39 (+0.69%)

Recommendations
Pfizer price target raised to $42 from $36 at Morgan Stanley » 08:34
07/30/20
07/30
08:34
07/30/20
08:34
PFE

Pfizer

$38.89 /

+0.265 (+0.69%)

, BNTX

BioNTech

$82.42 /

-2.875 (-3.37%)

Morgan Stanley analyst…

Morgan Stanley analyst David Risinger raised the firm's price target on Pfizer (PFE) to $42 from $36 after he added risk-adjusted COVID-19 vaccine sales to his model. The analyst, who awaits Phase 3 efficacy and safety data and competitor's results, currently assumes 65% odds of COVID vaccine success for Pfizer and partner BioNTech (BNTX). While Risinger thinks Pfizer appears set to grow, he sees some uncertainties for the company's key Ibrance and Prevnar franchises, leading him to keep an Equal Weight rating on the shares.

ShowHide Related Items >><<
PFE Pfizer
$38.89 /

+0.265 (+0.69%)

BNTX BioNTech
$82.42 /

-2.875 (-3.37%)

PFE Pfizer
$38.89 /

+0.265 (+0.69%)

07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
BNTX BioNTech
$82.42 /

-2.875 (-3.37%)

07/21/20
Fly Intel: Top five analyst upgrades
07/21/20 Canaccord
BioNTech price target raised to $97 from $75 at Canaccord
07/20/20 BofA
BioNTech upgraded to Buy from Neutral at BofA
PFE Pfizer
$38.89 /

+0.265 (+0.69%)

BNTX BioNTech
$82.42 /

-2.875 (-3.37%)

  • 23
    Jul
  • 06
    Feb
  • 10
    Oct
PFE Pfizer
$38.89 /

+0.265 (+0.69%)

BNTX BioNTech
$82.42 /

-2.875 (-3.37%)

PFE Pfizer
$38.89 /

+0.265 (+0.69%)

BNTX BioNTech
$82.42 /

-2.875 (-3.37%)

PFE Pfizer
$38.89 /

+0.265 (+0.69%)

BNTX BioNTech
$82.42 /

-2.875 (-3.37%)

Recommendations
Pfizer price target raised to $43 from $38 at Mizuho » 06:49
07/30/20
07/30
06:49
07/30/20
06:49
PFE

Pfizer

$38.89 /

+0.265 (+0.69%)

Mizuho analyst Vamil…

Mizuho analyst Vamil Divan raised the firm's price target on Pfizer to $43 from $38 and keeps a Buy rating on the shares. Following a "solid" Q2 report, the shares can see further upside with continued positive progress on the vaccine front, Divan tells investors in a research note.. Further, the "strong execution" Pfizer is demonstrating in the current environment bodes well for "New Pfizer" going forward, says the analyst.

ShowHide Related Items >><<
PFE Pfizer
$38.89 /

+0.265 (+0.69%)

PFE Pfizer
$38.89 /

+0.265 (+0.69%)

07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
07/14/20 Mizuho
IPR not likely to impact uniQure's ability to commercialize AMT-061, says Mizuho
PFE Pfizer
$38.89 /

+0.265 (+0.69%)

PFE Pfizer
$38.89 /

+0.265 (+0.69%)

PFE Pfizer
$38.89 /

+0.265 (+0.69%)

PFE Pfizer
$38.89 /

+0.265 (+0.69%)

Wednesday
Hot Stocks
Bristol-Myers, bluebird submit BLA to FDA for idecabtagene vicleucel » 16:17
07/29/20
07/29
16:17
07/29/20
16:17
BMY

Bristol-Myers

$59.16 /

-0.24 (-0.40%)

, BLUE

Bluebird Bio

$62.34 /

-3.36 (-5.11%)

Bristol Myers Squibb…

Bristol Myers Squibb (BMY) and bluebird bio, Inc. (BLUE) announced the submission of their Biologics License Application to the U.S. Food and Drug Administration for idecabtagene vicleucel, the companies' investigational B-cell maturation antigen-directed chimeric antigen receptor T cell immunotherapy, for the treatment of adult patients with relapsed and refractory multiple myeloma. This submission provides further details on the Chemistry, Manufacturing and Controls module to address the outstanding regulatory requests from the FDA in May 2020 following the original BLA submission from March 2020. The submission is based on results from the pivotal Phase 2 KarMMa study evaluating the efficacy and safety of ide-cel in relapsed and refractory multiple myeloma patients exposed to an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody. Results from the study were shared during an oral presentation as part of the American Society of Clinical Oncology 2020 Virtual Scientific Program.

ShowHide Related Items >><<
BMY Bristol-Myers
$59.16 /

-0.24 (-0.40%)

BLUE Bluebird Bio
$62.34 /

-3.36 (-5.11%)

BMY Bristol-Myers
$59.16 /

-0.24 (-0.40%)

07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
07/22/20 Morgan Stanley
Morgan Stanley sees 'encouraging news' coming in near-term for Bristol-Myers
BLUE Bluebird Bio
$62.34 /

-3.36 (-5.11%)

06/12/20 Piper Sandler
Bluebird Bio update 'modestly positive,' says Piper Sandler
06/10/20 Stifel
Stifel says Bluebird setup 'downside biased,' Crispr's 'upside biased' into EHA
05/13/20 Stifel
Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel
05/13/20 Piper Sandler
Bluebird should be able to easily address RTF issues, says Piper Sandler
BMY Bristol-Myers
$59.16 /

-0.24 (-0.40%)

BLUE Bluebird Bio
$62.34 /

-3.36 (-5.11%)

  • 19
    May
BMY Bristol-Myers
$59.16 /

-0.24 (-0.40%)

BMY Bristol-Myers
$59.16 /

-0.24 (-0.40%)

BLUE Bluebird Bio
$62.34 /

-3.36 (-5.11%)

BMY Bristol-Myers
$59.16 /

-0.24 (-0.40%)

Periodicals
Moderna plans to price COVID vaccine at $50-$60 per course, FT reports » 08:17
07/29/20
07/29
08:17
07/29/20
08:17
MRNA

Moderna

$81.45 /

+1.55 (+1.94%)

, PFE

Pfizer

$39.01 /

+1.415 (+3.76%)

, AZN

AstraZeneca

$56.30 /

-0.29 (-0.51%)

Moderna (MRNA) is…

Moderna (MRNA) is planning to price its potential coronavirus vaccine at $50-$60 per course, or $25-$30 per dose, for high-income countries, The Financial Times' Donato Paolo Mancini, Clive Cookson and Hannah Kuchler report. The price appears to be higher than that agreed by Pfizer (PFE) and BioNTech last week in a pre-order deal with the U.S. government at $19.50 per dose. Meanwhile AstraZeneca's (AZN) deal with the Netherlands, Germany, France and Italy for its potential vaccine, worked out to $3-$4 per dose, according to SVB Leerink analyst Geoffrey Porges. Reference Link

ShowHide Related Items >><<
PFE Pfizer
$39.01 /

+1.415 (+3.76%)

MRNA Moderna
$81.45 /

+1.55 (+1.94%)

AZN AstraZeneca
$56.30 /

-0.29 (-0.51%)

MRNA Moderna
$81.45 /

+1.55 (+1.94%)

07/27/20 Piper Sandler
Piper reiterates $134 Moderna target on start of Phase III vaccine trial
07/27/20 BMO Capital
Moderna price target lowered to $94 from $112 at BMO Capital
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
07/23/20 SVB Leerink
Moderna initiated with a Market Perform at SVB Leerink
PFE Pfizer
$39.01 /

+1.415 (+3.76%)

07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
07/14/20 Mizuho
IPR not likely to impact uniQure's ability to commercialize AMT-061, says Mizuho
AZN AstraZeneca
$56.30 /

-0.29 (-0.51%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
PFE Pfizer
$39.01 /

+1.415 (+3.76%)

MRNA Moderna
$81.45 /

+1.55 (+1.94%)

AZN AstraZeneca
$56.30 /

-0.29 (-0.51%)

  • 19
    May
  • 12
    Feb
PFE Pfizer
$39.01 /

+1.415 (+3.76%)

MRNA Moderna
$81.45 /

+1.55 (+1.94%)

AZN AstraZeneca
$56.30 /

-0.29 (-0.51%)

PFE Pfizer
$39.01 /

+1.415 (+3.76%)

MRNA Moderna
$81.45 /

+1.55 (+1.94%)

AZN AstraZeneca
$56.30 /

-0.29 (-0.51%)

PFE Pfizer
$39.01 /

+1.415 (+3.76%)

MRNA Moderna
$81.45 /

+1.55 (+1.94%)

AZN AstraZeneca
$56.30 /

-0.29 (-0.51%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.